Berkeley Lights Unveils the Beacon™ Platform for Massively Parallel Selection and Annotation of Single Cells
Platform Fully Automates Complex Single Cell Workflows with Precise, Quality-Controlled Operations
EMERYVILLE, Calif., June 3, 2016 /PRNewswire/ -- Berkeley Lights, Inc. today announced the unveiling of its new Beacon platform that accelerates cell line development and empowers immuno-oncology research. The Beacon transforms complex, multistep workflows involving a wide variety of cells and cellular interactions into precise, quality-controlled, walk away operations. For the first time, individual cells can be isolated, cultured, and assayed on a single opto-fluidic chip supporting a multitude of applications.
The Beacon platform enables time line compression of cell line development through faster identification of top secreting cells with direct correlation to quantitative standard curves, while maintaining greater than 99% monoclonality. Unique, automated workflows can shorten the typical development timeline by as much as three months, which may result in significant cost savings, as well as potentially minimizing production costs with potentially higher yields.
As an all-purpose single cell based immunology discovery platform, the Beacon platform enables workflows for the isolation, annotation, stimulation, and culturing of human primary cells. The ability to work at a single cell level with B-cells, multiple types of T-cells, myeloid cells, and other cells of interest for culturing and functional assays can provide a better understanding of the immune system and cell–to-cell interactions. Cells of interest can be exported for further "omic" studies. The Beacon platform brings scalability, automation, and precision to studies that are currently tedious and difficult or impossible to perform.
"We founded Berkeley Lights to create breakthrough platforms that automate biomedical processes by fusing world class engineering with world class biology. The Beacon is our first platform that delivers the integration, precision and scalability needed to advance cell line development, antibody discovery and immuno-oncology research," stated Igor Khandros, PhD, co-founder and chief executive officer at Berkeley Lights. "Our platforms will allow customers the ability to interact with cells in ways never before possible and ultimately enable our vision of delivering distributed, copy exact manufacturing of cellular therapies."
The Beacon platform is powered by BLI's proprietary OptoSelect™ technology that enables the precise movement, positioning, and interaction of cells on an opto-fluidic chip. The Beacon platform is now available for order.
To learn more about the Beacon, please visit http://www.berkeleylights.com/ or contact BLI directly at 510-858-2855 to schedule an onsite meeting.
Berkeley Lights' Beacon Platform is: FOR RESEARCH USE ONLY. Not for use in diagnostic procedures.
About Berkeley Lights
Founded in 2011 and headquartered in Emeryville, CA, Berkeley Lights, Inc. has developed technology, platforms and devices that enable opto-nanofluidic biomedical engineering with the highest level of integration. Berkeley Lights' core belief is that biomedical challenges yield to world-class engineering, and the company is applying its capabilities to address unmet research needs in BioPharma, Cellular Immuno-Oncology, and Autologous T-cell Therapies. Berkeley Lights' integrated platforms transform complex, multi-step workflows involving a wide variety of cells and assays into precise, repeatable, quality-controlled, walk-away operations. For more information, visit http://www.berkeleylights.com/, follow @Berkeley_Lights on Twitter or on our LinkedIn page.
Berkeley Lights, the Berkeley Lights logo, Beacon, LightHouse and OptoSelect are trademarks of Berkeley Lights, Inc. All other product, trademark, company or service names mentioned herein are the property of the irrespective owners.
Logo - http://photos.prnewswire.com/prnh/20151209/294794LOGO
SOURCE Berkeley Lights, Inc.
Share this article